We are a global biopharmaceutical company committed to developing drugs for the treatment of a range of severe skin disorders.

CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe. In December 2014 the European Commission granted SCENESSE® marketing authorisation under exceptional circumstances for the prevention of phototoxicity in adult patients with EPP. Further trials of SCENESSE® are underway in the pigmentary disorder vitiligo.

Our website has been developed to help share our expertise on the interaction of light and human skin as well as provide a thorough overview of our global drug development programs.

Latest Company Announcements

26 March 2018

CLINUVEL Newsletter - March 2018

The erythropoietic protoporphyria (EPP) Expert Meeting in Vienna on 16 March has had quite an impact on our global teams working in the fields of photomedicine and melanocortins.

Read More
19 March 2018


CLINUVEL PHARMACEUTICALS LTD today announced the results of the third European meeting on erythropoietic protoporphyria (EPP) held in Vienna, Austria, on Friday 16 March.

Read More
21 February 2018

CLINUVEL sustains profitability first-half of year

CLINUVEL PHARMACEUTICALS LTD today announced financial results for the half year ended 31 December 2017, reporting net profit after tax of A$1.41m, and total revenues of A$7.19m.

Read More
13 February 2018

CLINUVEL unveils new global positioning

CLINUVEL PHARMACEUTICALS LTD today released its new global Company positioning including the unveiling of a new Group identity and website.

Read More
12 February 2018

CLINUVEL Newsletter - February 2018

We started this year with limitless optimism and energy, and I attribute this to a foundation of internal changes made over the past 16 months

Read More
31 January 2018

Appendix 3X - Karen Agersborg

Appendix 3X - Karen Agersborg

Read More

Quick Links